Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q9JN
|
||||
| Former ID |
DNC013511
|
||||
| Drug Name |
1-(5-methyloxazol-2-yl)-7-phenylheptan-1-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [529193] | ||
| Formula |
C17H21NO2
|
||||
| Canonical SMILES |
CC1=CN=C(O1)C(=O)CCCCCCC2=CC=CC=C2
|
||||
| InChI |
1S/C17H21NO2/c1-14-13-18-17(20-14)16(19)12-8-3-2-5-9-15-10-6-4-7-11-15/h4,6-7,10-11,13H,2-3,5,8-9,12H2,1H3
|
||||
| InChIKey |
PBGYMEUYJWSKDY-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Fatty-acid amide hydrolase | Target Info | Inhibitor | [529193] | |
| BioCyc Pathway | Anandamide degradation | ||||
| KEGG Pathway | Retrograde endocannabinoid signaling | ||||
| PANTHER Pathway | Anandamide degradation | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.